title: Diabetes: Immunotherapy for T1DM--still not there yet.
abstract: Alefacept, a fusion protein approved for psoriasis, has been trialled in patients with new-onset type 1 diabetes mellitus. However, the withdrawal of the drug from the US market and the unmet primary end point do not raise hope for this drug, even though some secondary end points were met and the study highlighted interesting immunological efficacy.
authors.affiliation: Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.
authors.forename: Raffaella
authors.initials: R
authors.lastname: Buzzetti
mesh_terms: D000077944:Alefacept; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
chemical_list: D011993:Recombinant Fusion Proteins; D000077944:Alefacept